Attention & Memory Impairments in Menopausal Women
| Status: | Completed |
|---|---|
| Conditions: | Cognitive Studies |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 45 - 60 |
| Updated: | 10/19/2013 |
| Start Date: | March 2011 |
| End Date: | June 2013 |
| Contact: | Jeanette Bradley, BA |
| Email: | jbradl@upenn.edu |
| Phone: | 215-573-8884 |
Attention & Memory Impairments in Menopausal Women: A Possible Role for Vyvanse?
The purpose of this study is to determine whether a medication called Vyvanse®
(lisdexamfetamine; LDX) has an impact on cognitive functioning, specifically measures of
sustained attention, verbal encoding and recall and working memory, in menopausal aged
women. LDX is a medication used to treat attention deficit hyperactivity disorder (ADHD).
The cognitive difficulties that menopausal women report experiencing are typical of adults
who are diagnosed with ADHD. The investigators will assess whether or not LDX is effective
in alleviating those cognitive disruptions when compared to a placebo.
Inclusion Criteria:
Women ages 45 to 60 will be eligible for this study if they:
- Are within 5 years of their last menstrual period;
- Are able to give written informed consent;
- Must have clear urine toxicology screen upon recruitment;
- Are fluent in written and spoken English;
- Must have negative urine pregnancy test if still menstruating.
Exclusion Criteria:
- History of seizures;
- History of cardiac disease including known cardiac defect or conduction abnormality;
- Abnormal electrocardiogram during screening;
- Use of estrogen therapy within previous 6 months;
- Current pregnancy or planning to become pregnant.
- Presence of a contraindication to treatment with stimulant medication; this would
include the presence of hypertension, coronary disease, atrial fibrillation, and
arrhythmia.
We found this trial at
1
site
Click here to add this to my saved trials
